The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Olutasidenib + azacitidine in patients with IDH1-mutated R/R AML: Pooled analysis from a phase I/II trial
|
Olutasidenib, a mutant IDH1 inhibitor, is approved by the U.S. FDA for the treatment of patients with IDH1mut R/R AML. A multicenter, open-label, phase I/II trial (NCT02719574) evaluated the efficacy and safety of olutasidenib combined with azacitidine in patients with IDH1mut R/R AML. The AML Hub previously reported on the 5-year follow-up data and the impact of long-term data on treatment strategies. A pooled analysis from multiple cohorts of this trial in patients who received olutasidenib + azacitidine was published by Cortes, et al.1 in the Journal of Hematology & Oncology, reporting the efficacy and tolerability of the combination in patients with IDH1mut R/R AML (N = 67). The primary efficacy endpoint was CR/CRh rate; secondary endpoints included ORR, 56-day transfusion independence rate, time to response, DoR, and OS.1 |
| Key learnings |
| The ORR was 51% and median time to first OR was 1.95 months. The CR/CRh rate was 31%, CR rate was 27%, and median CR duration was 20.3 months. The median OS was 12.9 months, with a median OS of 30.6 months among patients achieving CR/CRh. |
| In patients without prior olutasidenib exposure (N = 51), CR/CRh rate was 37%, CR rate was 31%, and ORR was 59%. In patients who achieved CR/CRh and were transfusion-dependent at baseline, transfusion independence rates were 64% (RBCs) and 57% (platelets). |
| Grade 3/4 AEs reported in ≥5% of patients were decreased platelet count (37%), RBC count (25%), neutrophil count (24%), and febrile neutropenia (19%). SEAEs occurred in 70% of patients and treatment discontinuation due to TEAE was reported in 6%. |
| Overall, promising efficacy and safety results suggest that olutasidenib plus azacitidine could be a viable therapeutic option for patients with IDH1mut R/R AML, which is a population with limited treatment options and a poor prognosis. |
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; CR, complete remission; CRh, CR with partial hematologic recovery; DoR, duration of response; OR, overall response; ORR, overall response rate; OS, overall survival; R/R, relapsed/refractory; RBC, red blood cell; SAE, serious adverse event, TEAE, treatment-emergent adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
